GlassScriptPhysician profile
Adam D Cox
NPI 1003158338
$3,208.42
in general payments reported to CMS, 2019-2025
24 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $68.49 · 2022: $14.75 · 2023: $178 · 2024: $1,565 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.27 | 2023-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $469.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $293.06 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Novo Nordisk INC | $274.73 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $247.73 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $209.57 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $132.69 | 2024-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.21 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $91.39 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $76.11 | 2024-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $75.95 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.18 | 2019-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $54.58 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $44.49 | 2025 | Rexulti |
| Astellas Pharma US INC | $41.92 | 2020-2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $38.08 | 2024 | Gemtesa |
| Boston Scientific Corporation | $34.26 | 2025 | Accolade Sr |
| Bayer Healthcare Pharmaceuticals INC. | $31.22 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.82 | 2025 | Caplyta |
| Mylan Specialty L.P. | $23.20 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $21.00 | 2024 | Auvelity |
| Nevro Corp. | $18.64 | 2024 | Senza |
| Novartis Pharmaceuticals Corporation | $17.06 | 2024 | |
| Currax Pharmaceuticals LLC | $14.61 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.